Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS-mutated mRNA vaccine (Sichuan University)
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a personalized neoantigen-based mRNA vaccine developed by Sichuan University for the treatment of advanced solid tumors harboring KRAS mutations. The vaccine platform is designed to deliver mRNA encoding specific KRAS-mutant neoantigens to stimulate the patient's immune system, specifically activating KRAS-specific CD4+ and CD8+ T-cell responses. The therapeutic goal is to convert 'immune-cold' tumors into responsive ones, potentially enhancing the efficacy of concurrent immunotherapies. It is currently being evaluated in a Phase 1 clinical trial (NCT06344156) as a monotherapy for various KRAS-mutant malignancies and as a neoadjuvant therapy in combination with the anti-PD-1 checkpoint inhibitor toripalimab and chemotherapy (pemetrexed and carboplatin) for lung adenocarcinoma. The trial, conducted in China, began in April 2024 and is expected to conclude in 2027.
- Other names
- KRAS mRNA vaccineKRAS-mutant mRNA vaccineKRAS-mutated mRNA vaccine-Sichuan University-solid tumors
Beyond the preview
Go deeper on KRAS-mutated mRNA vaccine (Sichuan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS-mutated mRNA vaccine (Sichuan University).